Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CASP2 | P42575 | 1/20 | 0.52 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.47 |
| ▸ | GLP1R | P43220 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23945978 | 1.00 | FAAH (0.57) | FAAHEPHX2TSHRRECQLCES2 | |
| SCHEMBL25123583 | 0.96 | FAAH (0.53) | FAAHEPHX2TSHRRECQLCES2 | |
| SCHEMBL25654294 | 0.93 | FAAH (0.56) | FAAHEPHX2TSHRRECQLCES2 | |
| SCHEMBL11846148 | 0.93 | FAAH (0.66) | FAAHEPHX2CES2CASP2NAAA | |
| SCHEMBL22802143 | 0.92 | FAAH (0.57) | FAAHEPHX2TSHRRECQLCES2 | |
| SCHEMBL21105956 | 0.92 | FAAH (0.57) | FAAHEPHX2TSHRRECQLCES2 | |
| SCHEMBL22525311 | 0.91 | TSHR (0.57) | FAAHTSHRRECQLGLP1R | |
| SCHEMBL22848588 | 0.91 | TSHR (0.57) | FAAHTSHRRECQLGLP1R | |
| SCHEMBL11840937 | 0.91 | TSHR (0.61) | FAAHEPHX2TSHRRECQLCES2 | |
| SCHEMBL22527258 | 0.91 | TSHR (0.57) | FAAHTSHRRECQLGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | FAAH 1771/4885EPHX2 1890/4885TSHR 3319/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | FAAH 1771/4885EPHX2 1890/4885TSHR 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.